VivoSeq
Neurology

Becker Muscular Dystrophy

9

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Becker muscular dystrophy is an early-stage landscape with 9 programs across 7 companies. The most active players are Eli Lilly, PTC Therapeutics, Edgewise Therapeutics, Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

80/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1P

PTC Therapeutics

2 programs

Phase 2E

Edgewise Therapeutics, Inc.

1 program

Phase 2Italfarmaco logo

Italfarmaco

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2C

Catalyst Biosciences

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSGene therapy111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed12 · 71%
Terminated3 · 18%
Enrolling by invitation1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Active, not recruiting·EEdgewise Therapeutics, Inc.·Phase 2·NCT05291091·244 enrolled
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Enrolling by invitation·EEdgewise Therapeutics, Inc.·Phase 2·NCT06066580·260 enrolled
Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
Completed·PPTC Therapeutics·Phase 2·NCT00592553·174 enrolled
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients
Completed·—·Phase 2·NCT01350154·17 enrolled
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
Completed·EEpirium Bio Inc.·Phase 1·NCT04386304·22 enrolled
Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada
Completed·PPTC Therapeutics·Phase 3·NCT01557400·94 enrolled
A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
Completed·RReveraGen BioPharma, Inc.·Phase 2·NCT05166109·46 enrolled
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial
Completed·IInCor Heart Institute·Phase 3·NCT02432885·76 enrolled
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Completed·NNationwide Children's Hospital·Phase 1·NCT01519349·15 enrolled
(-)- Epicatechin Becker Muscular Dystrophy
Completed·—·Phase 2·NCT03236662·2 enrolled
A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
Completed·EEdgewise Therapeutics, Inc.·Phase 1·NCT05160415·12 enrolled
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
Completed·Italfarmaco logoItalfarmaco·Phase 2·NCT03238235·51 enrolled
Tadalafil in Becker Muscular Dystrophy
Completed·—·Phase 4·NCT01070511·48 enrolled
Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)
Completed·—·Phase 1/2·NCT01856868·7 enrolled
The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy
Terminated·—·Phase 1·NCT02653833·6 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)